Search

Your search keyword '"Beta-blockers"' showing total 32 results
Start Over Descriptor "Beta-blockers" Journal cardiovascular drugs and therapy
32 results on '"Beta-blockers"'

4. Role of Beta-Adrenergic Receptor Gene Polymorphisms in the Long-Term Effects of Beta-Blockade with Carvedilol in Patients with Chronic Heart Failure

Author

Alessia Romeo, Marco Metra, N. Pezzali, Raffaele Giubbini, Carlo Lombardi, Francesco Donato, Loredana Covolo, Livio Dei Cas, Valerio Zacà, Luca Bettari, Silvia Bugatti, and Umberto Gelatti

Subjects
gene polymorphisms, Male, Aging, Cardiomyopathy, Blood Pressure, Radionuclide ventriculography, Linkage Disequilibrium, Ventricular Function, Left, Propanolamines, Ventricular Dysfunction, Left, Heart Rate, Heart failure, beta-blockers, Pharmacology (medical), Carvedilol, Ejection fraction, Ventricular Remodeling, Homozygote, General Medicine, Middle Aged, Treatment Outcome, Cardiology, Female, Cardiology and Cardiovascular Medicine, medicine.drug, Adult, medicine.medical_specialty, Genotype, Adrenergic beta-Antagonists, Carbazoles, Polymorphism, Single Nucleotide, Oxygen Consumption, Internal medicine, Receptors, Adrenergic, beta, Heart rate, medicine, Humans, Pulmonary Wedge Pressure, Ventricular remodeling, Aged, Heart Failure, Pharmacology, business.industry, Stroke Volume, medicine.disease, Blood pressure, Vascular Resistance, Receptors, Adrenergic, beta-2, Receptors, Adrenergic, beta-1, business
Abstract

Beta-blockers are mainstay of current treatment of heart failure (HF). Beta-adrenergic receptors (AR) single nucleotide gene polymorphisms (SNPs) may influence the sensitivity and density of beta-AR. We assessed the relation between three common beta-AR SNPs and the response to carvedilol administration.We studied 183 consecutive patients with chronic HF due to ischemic or nonischemic cardiomyopathy, a LV ejection fraction (LVEF)or = 0.35, not previously treated with beta-blockers. Each patient underwent gated-SPECT radionuclide ventriculography, cardiopulmonary exercise testing and invasive hemodynamic monitoring at baseline and after 12 months of carvedilol administration at maintenance dosages. The beta1-AR gene Arg389Gly and the beta2-AR gene Arg16Gly SNPs were not related to the response to carvedilol administration. Homozygotes for the Glu27Glu allele showed a greater increase in the LVEF, compared to the other patients (+13.0 +/- 12.2% versus +7.1 +/- 8.1% in the Gln27Gln homozygotes, and 8.3 +/- 11.4% units in the Gln27Glu heterozygotes; p = 0.022 by ANOVA). Glu27Glu homozygotes also showed a greater decline in the pulmonary wedge pressure both at rest and at peak exercise. Gln27Glu SNP was selected amongst the determinants of the LVEF response to carvedilol at multivariable analysis, in addition to the cause of cardiomyopathy, baseline systolic blood pressure and the dose of carvedilol administered.Beta1-AR Arg389Gly and beta2-AR Arg16Gly SNPs are not related to the response to carvedilol therapy. In contrast, the Gln27Glu SNP is a determinant of the LVEF response to this agent in patients with chronic HF.

Published
2010
Full Text
View/download PDF

24. Do pharmacological differences among beta-blockers affect their clinical efficacy in heart failure?

Author

Gianfranco Sinagra, Andrea Di Lenarda, Gastone Sabbadini, Di Lenarda, A, Sabbadini, Gastone, and Sinagra, Gianfranco

Subjects
medicine.medical_specialty, beta-blockers, heart failure, Adrenergic beta-Antagonists, Carbazoles, Pharmacology, Affect (psychology), Propanolamines, Internal medicine, medicine, Bisoprolol, Humans, Pharmacology (medical), Clinical efficacy, Beta (finance), Metoprolol, Randomized Controlled Trials as Topic, Heart Failure, business.industry, General Medicine, medicine.disease, Heart failure, Cardiology, beta-blocker, Carvedilol, Receptors, Adrenergic, beta-2, Receptors, Adrenergic, beta-1, Cardiology and Cardiovascular Medicine, business, medicine.drug
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results